Licensed indications | Infliximab | Etanercept | Adalimumab | Golimumab | Certolizumab |
Rheumatoid arthritis | +§ | +§,ƒ | +§,ƒ | +§ | +§,ƒ |
Active disease and inadequate response to DMARD including MTX# | +§ | +§,ƒ | +§,ƒ | +§ | +§,ƒ |
Patients with severe and progressive/erosive disease without prior DMARD therapy# | Dosing:3 mg·kg−1 i.v. week 0, 2, 6 then 8-weeklyInadequate response: increase to 7.5 mg·kg−1 8-weekly or 3 mg·kg−1 4-weekly | Dosing:25 mg sc twice a week or 50 mg sc once a week | Dosing40 mg sc 2-weekly | Dosing50 mg sc 4-weekly | Dosing400 mg sc week 0 and 2, then once a month |
Patients with moderately to severely active disease¶ | |||||
Ankylosing spondylitis | + | + | + | + | |
Inadequate response to conventional therapy (i.e. NSAID)# | Dosing:3 mg·kg−1 i.v. week 0, 2, 6 then 6–8-weekly | Dosing:25 mg sc twice a week or 50 mg sc once a week | Dosing40 mg sc 2-weekly | Dosing50 mg sc 4-weekly | |
Active disease¶ | |||||
Psoriatic arthritis | +§,ƒ | + | + | +§,ƒ | |
Active disease and inadequate response to DMARD including MTX# | Dosing:3 mg·kg−1 i.v. week 0, 2, 6 then 8-weekly | Dosing:25 mg sc twice a week or 50 mg sc once a week | Dosing40 mg sc 2-weekly | Dosing50 mg sc 4-weekly | |
Active arthritis¶ | |||||
Juvenile idiopathic arthritis | + | + | |||
Age >4 and <18 yrs and active disease and inadequate response to or intolerance of DMARD including MTX# | Dosing:0.4 mg·kg−1 sc twice a week | Dosing40 mg sc 2-weekly | |||
Patients with moderately to severely active disease¶ | |||||
Crohn's disease | Dosing5 mg·kg−1 i.v. week 0, 2, 6 then 8-weeklyIf ineffective increase to 10 mg·kg−1 every 8 weeks | Not used | Dosing160 mg sc, followed by 80 mg sc then 40 mg every second week | Not approved | Dosing400 mg sc at weeks 0, 2 and 4 followed by 400 mg every 4 weeks (not yet approved in Europe) |
Ulcerative colitis | Dosing5 mg·kg−1 i.v. week 0, 2, 6 then 8-weeklyIf ineffective increase to 10 mg·kg−1 every 8 weeks | Not used | Not yet approved | Not yet approved | Not yet approved |
Psoriasis | Dosing5 mg·kg−1 i.v. at weeks 0, 2, 6 and then every 8 weeks | Dosing25 mg sc twice weekly or 50 mg weekly up to 24 weeks or 50 mg twice weekly up to 12 weeks and weekly thereafter | Dosing80 mg sc week 0, 40 mg week 1 and alternate weeks thereafter | No current data | No current data |
Very severe plaque psoriasis PASI >20, DLQI >18 and failure or contraindication to 2nd line drugs (MTX, cyclosporine, PUVA) | |||||
Severe plaque psoriasis PASI >10, DLQI >10 and failure or contraindication to 2nd line drugs (MTX, cyclosporine, PUVA) |
DMARD: disease-modifying anti-rheumatic drug; MTX: methotrexate; NSAID: nonsteroidal anti-rheumatic drug; PASI: Psoriasis Area Severity Index; DLQI: Dermatology Life Quality Index; PUVA: psoralen ultraviolet A-range; sc: subcutaneously. #: plus MTX; ¶: without MTX if contraindicated or not tolerated; §: European Medicines Agency approved indication; ƒ: Federal Drug Administration approved indication.